{"id":16903,"date":"2022-12-22T10:05:56","date_gmt":"2022-12-22T10:05:56","guid":{"rendered":"https:\/\/interhospi.com\/?p=16903"},"modified":"2022-12-28T09:08:24","modified_gmt":"2022-12-28T09:08:24","slug":"rqm-launches-reimbursement-division","status":"publish","type":"post","link":"https:\/\/interhospi.com\/rqm-launches-reimbursement-division\/","title":{"rendered":"RQM+ launches reimbursement division"},"content":{"rendered":"
\n

<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

RQM+ launches reimbursement division<\/h1>\/ in Featured Articles<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

RQM+, the leading MedTech service provider with the world\u2019s largest global team of regulatory and quality experts, has launched its reimbursement division. RQM+ now provides comprehensive reimbursement services in addition to regulatory, quality, clinical and laboratory services \u2013 supporting market access throughout the entire product lifecycle for medical devices and diagnostics.
\n<\/strong><\/p>\n

<\/p>\n

\u201cMedTech manufacturers are seeking reimbursement partners to manage increasingly complex challenges and ensure that reimbursement strategies are developed in tandem with regulatory strategies,\u201d said CEO Margaret Keegan. \u201cWe are honoured to have Dr Daniel Lace, who is widely recognized as one of the industry\u2019s most trusted reimbursement experts, leading our new division. He will also support all our services as our chief medical officer (CMO). As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ offers its customers unparalleled expertise in both regulatory and reimbursement, ensuring patient access to life-improving technologies faster than ever before.\u201d<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
<\/div><\/div><\/div>
\n

Daniel Lace MD, CPE, FAAPL has been appointed the new chief medical officer of RQM+<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

RQM+ reimbursement services range from initial reimbursement strategy development to post-approval market access support. \u201cIt is a privilege to serve as CMO \u2013 providing strategic guidance for reimbursement as well as related services and technologies,\u201d said Lace. \u201cWe look forward to helping customers navigate the complicated reimbursement and market access environment. We will use our extensive experience with the latest reimbursement requirements and value-based compensation models, as well as key payment trends, to provide customized support that fits each company\u2019s needs.\u201d<\/p>\n<\/div><\/section>
\n